The New England journal of medicine, 2018-01, Vol.378 (4), p.354-369
- Zeuzem, Stefan
- Foster, Graham R
- Wang, Stanley
- Asatryan, Armen
- Gane, Edward
- Feld, Jordan J
- Asselah, Tarik
- Bourlière, Marc
- Ruane, Peter J
- Wedemeyer, Heiner
- Pol, Stanislas
- Flisiak, Robert
- Poordad, Fred
- Chuang, Wan-Long
- Stedman, Catherine A
- Flamm, Steven
- Kwo, Paul
- Dore, Gregory J
- Sepulveda-Arzola, Gladys
- Roberts, Stuart K
- Soto-Malave, Ruth
- Kaita, Kelly
- Puoti, Massimo
- Vierling, John
- Tam, Edward
- Vargas, Hugo E
- Bruck, Rafi
- Fuster, Francisco
- Paik, Seung-Woon
- Felizarta, Franco
- Kort, Jens
- Fu, Bo
- Liu, Ran
- Ng, Teresa I
- Pilot-Matias, Tami
- Lin, Chih-Wei
- Trinh, Roger
- Mensa, Federico J
2018
Volltextzugriff (PDF)
Details
- Autor(en) / Beteiligte
- Zeuzem, Stefan
- Foster, Graham R
- Wang, Stanley
- Asatryan, Armen
- Gane, Edward
- Feld, Jordan J
- Asselah, Tarik
- Bourlière, Marc
- Ruane, Peter J
- Wedemeyer, Heiner
- Pol, Stanislas
- Flisiak, Robert
- Poordad, Fred
- Chuang, Wan-Long
- Stedman, Catherine A
- Flamm, Steven
- Kwo, Paul
- Dore, Gregory J
- Sepulveda-Arzola, Gladys
- Roberts, Stuart K
- Soto-Malave, Ruth
- Kaita, Kelly
- Puoti, Massimo
- Vierling, John
- Tam, Edward
- Vargas, Hugo E
- Bruck, Rafi
- Fuster, Francisco
- Paik, Seung-Woon
- Felizarta, Franco
- Kort, Jens
- Fu, Bo
- Liu, Ran
- Ng, Teresa I
- Pilot-Matias, Tami
- Lin, Chih-Wei
- Trinh, Roger
- Mensa, Federico J
- Titel
- Glecaprevir–Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection
- Ist Teil von
- The New England journal of medicine, 2018-01, Vol.378 (4), p.354-369
- Ort / Verlag
- United States: Massachusetts Medical Society
- Erscheinungsjahr
- 2018
- Quelle
- MEDLINE
- Beschreibungen/Notizen
- In two randomized, open-label trials, the combination of glecaprevir and pibrentasvir given once daily for 8 or 12 weeks achieved high rates of sustained virologic response in patients with HCV genotype 1 or 3 infection who did not have cirrhosis.
- Sprache
- Englisch
- Identifikatoren
- ISSN: 0028-4793eISSN: 1533-4406DOI: 10.1056/NEJMoa1702417Titel-ID: cdi_proquest_journals_1991179192
- Format
- –
- Schlagworte
- Adult, Aged, Aged, 80 and over, Antiviral agents, Antiviral Agents - adverse effects, Antiviral Agents - therapeutic use, Antiviral drugs, Benzimidazoles - adverse effects, Benzimidazoles - therapeutic use, Cirrhosis, Clinical trials, Drug Administration Schedule, Drug Combinations, Female, Genotype, Genotype & phenotype, Genotypes, Hepacivirus - genetics, Hepatitis, Hepatitis C, Hepatitis C, Chronic - drug therapy, Hepatitis C, Chronic - virology, Humans, Imidazoles - adverse effects, Imidazoles - therapeutic use, Infections, Interferon, Liver cirrhosis, Male, Medicine, Middle Aged, Patients, Quinoxalines - adverse effects, Quinoxalines - therapeutic use, RNA, Viral - blood, Sofosbuvir - adverse effects, Sofosbuvir - therapeutic use, Sulfonamides - adverse effects, Sulfonamides - therapeutic use, Viral Load